These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 627132)

  • 1. Physiologic disposition of lergotrile.
    Rubin A; Lemberger L; Dhahir P; Warrick P; Crabtree RE; Obermeyer BD; Wolen RL; Rowe H
    Clin Pharmacol Ther; 1978 Mar; 23(3):272-80. PubMed ID: 627132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologic disposition of pergolide.
    Rubin A; Lemberger L; Dhahir P
    Clin Pharmacol Ther; 1981 Aug; 30(2):258-65. PubMed ID: 6113911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The treatment of hyperprolactinemia with a new ergot derivative, lergotrile mesylate.
    Sherman BM; Swanson JA; Chapler FK
    Fertil Steril; 1978 Mar; 29(3):291-5. PubMed ID: 565303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The disposition of l-3-[(dimethylamino)-(m-dioxan-5-yl)methyl]pyridine in man.
    Rubin A; Dhahir PH; Crabtree RE; Henry DP
    Drug Metab Dispos; 1979; 7(3):149-54. PubMed ID: 38085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Parkinson's disease with lergotrile mesylate.
    Lieberman A; Estey E; Kupersmith M; Gopinathan G; Goldstein M
    JAMA; 1977 Nov; 238(22):2380-2. PubMed ID: 335094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-demethylation of lergotrile by Streptomyces platensis.
    Davis PJ; Glade JC; Clark AM; Smith RV
    Appl Environ Microbiol; 1979 Nov; 38(5):891-3. PubMed ID: 44446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of lergotrile on galactorrhea and gonadotropin secretion.
    Cleary RE; Crabtree R; Lemberger L
    J Clin Endocrinol Metab; 1975 May; 40(5):830-3. PubMed ID: 165221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between lergotrile and bromocriptine in parkinsonism.
    Teychenne PF; Pfeiffer RF; Bern SM; McInturff D; Calne DB
    Ann Neurol; 1978 Apr; 3(4):319-24. PubMed ID: 666273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on the antiparkinsonism efficacy of lergotrile.
    Lieberman A; Miyamoto T; Battista AF; Goldstein M
    Neurology; 1975 May; 25(5):459-62. PubMed ID: 166332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the dopamine agonist, lergotrile mesylate, on circulating anterior pituitary hormones in man.
    Thorner MO; Ryan SM; Wass JA; Jones A; Bouloux P; Williams S; Besser GM
    J Clin Endocrinol Metab; 1978 Aug; 47(2):372-8. PubMed ID: 45463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross tolerance between two dopaminergic ergot derivatives--bromocriptine and lergotrile.
    Teychenne PF; Rosin AJ; Plotkin CN; Calne DB
    Br J Clin Pharmacol; 1980 Jan; 9(1):47-50. PubMed ID: 6101955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lergotrile in the treatment of parkinsonism.
    Klawans HL; Goetz CG; Volkman P; Nausieda PA; Weiner WJ
    Neurology; 1978 Jul; 28(7):699-702. PubMed ID: 566868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of the effects of CB-154 and lergotrile mesylate on prolactin and growth hormone secretion in mice.
    Sinha YN; Salocks CB; VanderLaan WP
    Horm Metab Res; 1976 Sep; 8(5):332-6. PubMed ID: 989755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disposition of zatosetron, a serotonin (5-HT3) receptor antagonist, in humans.
    Franz PM; Mattiuz EL; Hatcher BL; DeSante KA; Breau AP; Occolowitz JL; Dorman DE; Schmid CR; Goldberg MJ; Rubin A
    Drug Metab Dispos; 1993; 21(2):249-54. PubMed ID: 8097693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
    Takusagawa S; van Lier JJ; Suzuki K; Nagata M; Meijer J; Krauwinkel W; Schaddelee M; Sekiguchi M; Miyashita A; Iwatsubo T; van Gelderen M; Usui T
    Drug Metab Dispos; 2012 Apr; 40(4):815-24. PubMed ID: 22269146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of dopamine agonist (Lergotrile mesylate) therapy on twenty-four hour secretion of prolactin in treated Parkinson's disease.
    Bell RD; Carruth A; Rosenberg RN; Boyar RM
    J Clin Endocrinol Metab; 1978 Oct; 47(4):807-11. PubMed ID: 45469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disposition and metabolism of 14C-rifapentine in healthy volunteers.
    Reith K; Keung A; Toren PC; Cheng L; Eller MG; Weir SJ
    Drug Metab Dispos; 1998 Aug; 26(8):732-8. PubMed ID: 9698286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism of lergotrile to 13-hydroxy lergotrile, a potent inhibitor of prolactin release in vitro.
    Parli CJ; Schmidt B; Shaar CJ
    Biochem Pharmacol; 1978 May; 27(9):1405-8. PubMed ID: 29651
    [No Abstract]   [Full Text] [Related]  

  • 19. Physiologic disposition of nabilone, a cannabinol derivative, in man.
    Rubin A; Lemberger L; Warrick P; Crabtree RE; Sullivan H; Rowe H; Obermeyer BD
    Clin Pharmacol Ther; 1977 Jul; 22(1):85-91. PubMed ID: 872500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism of labetalol by animals and man.
    Martin LE; Hopkins R; Bland R
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):695-710. PubMed ID: 990152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.